MarketCap
Facebook
X
Telegram
Arena Pharmaceuticals Balance Sheet 2021-2008 | ARNA
Brief overview of Arena Pharmaceuticals's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2016 and 2020.
The asset base grew from $169 million to $1.2 billion, or +604.5%. Average annual growth of roughly 62.9% was strong.
Growth in the asset base was not matched by liabilities: +604.5% versus -14.3%. The balance sheet moved in a more conservative direction.
Internal capital represents 90.7% of the balance sheet, previously 23.6%. This is a strong capital position.
Cash equals 18.4% of the balance sheet, compared with 53.7% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$1.5 billion. It should be assessed alongside historical profits and capital distributions.
What the balance sheet shows
Arena Pharmaceuticals's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Arena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-214 M | - | - | - | - | -25.4 M | -87.9 M | -92.5 M | -149 M | -81.6 M | -42.9 M | - | - | - |
Long Term Debt |
8.3 M | - | - | - | - | - | - | - | - | - | 14.7 M | - | - | - |
Long Term Debt Current |
1.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 52.2 M | 57.7 M | 50.7 M | 59.8 M | 64.7 M | 153 M | 162 M | 177 M | 133 M | 132 M | - | - | - |
Total Current Liabilities |
66.3 M | 58.1 M | 45 M | 29.9 M | 72.3 M | 63.9 M | 49.9 M | 67.4 M | 70.7 M | 29.9 M | 14.4 M | 36.9 M | - | - |
Total Liabilities |
- | 110 M | 103 M | 80.6 M | 132 M | 129 M | 203 M | 229 M | 248 M | 163 M | 147 M | - | - | - |
Deferred Revenue |
- | - | - | - | 1.11 M | 4.41 M | 21.4 M | 15.2 M | 37.9 M | 15.5 M | 3.47 M | 3.85 M | - | - |
Retained Earnings |
-2.12 B | -1.51 B | -1.1 B | -1.5 B | -1.49 B | -1.4 B | -1.38 B | -1.27 B | -1.21 B | -1.19 B | -1.08 B | -971 M | - | - |
Total Assets |
785 M | 1.19 B | 1.17 B | 687 M | 339 M | 169 M | 257 M | 276 M | 340 M | 261 M | 157 M | 266 M | - | - |
Cash and Cash Equivalents |
225 M | 220 M | 243 M | 161 M | 159 M | 90.7 M | 156 M | 163 M | 222 M | 156 M | 57.6 M | 151 M | 94.7 M | 73.3 M |
Book Value |
785 M | 1.08 B | 1.07 B | 606 M | 207 M | 40.4 M | 53.5 M | 47.3 M | 91.9 M | 98.6 M | 10.6 M | 266 M | - | - |
Total Shareholders Equity |
673 M | 1.08 B | 1.07 B | 606 M | 207 M | 39.9 M | 53.5 M | 47.3 M | 91.9 M | 98.6 M | 10.6 M | 80 M | 74.6 M | 118 M |
All numbers in USD currency
Quarterly Balance Sheet Arena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 8.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 800 K | 800 K | 800 K | 1.11 M | 28 M | 31 M | 33.2 M | 4.41 M | 22.5 M | 20 M | 22.2 M | 21.4 M | 23.2 M | 26.9 M | 26.3 M | 15.2 M | 19.9 M | 32.5 M | 35.4 M | 37.9 M | 29.2 M | 7.8 M | 15.4 M | 15.5 M | 3.5 M | 3.85 M | 3.51 M | 3.47 M | 3.86 M | 3.87 M | 3.47 M |
Retained Earnings |
- | - | - | - | -2.12 B | -1.97 B | -1.77 B | -1.63 B | -1.51 B | -1.39 B | -1.29 B | -1.2 B | -1.1 B | -1.01 B | -942 M | -880 M | -1.5 B | -1.57 B | -1.53 B | -1.5 B | -1.49 B | -1.48 B | -1.44 B | -1.42 B | -1.4 B | -1.44 B | -1.42 B | -1.4 B | -1.38 B | -1.35 B | -1.32 B | -1.29 B | -1.27 B | -1.24 B | -1.23 B | -1.23 B | -1.21 B | -1.18 B | -1.17 B | -1.21 B | -1.19 B | -1.17 B | -1.15 B | -1.11 B | -1.08 B | -1.06 B | -1.03 B | -1.08 B |
Total Assets |
- | - | - | - | 785 M | 901 M | 1.08 B | 1.18 B | 1.19 B | 1.28 B | 1.34 B | 1.09 B | 1.17 B | 1.24 B | 1.28 B | 1.33 B | 687 M | 610 M | 638 M | 685 M | 339 M | 348 M | 189 M | 140 M | 169 M | 210 M | 218 M | 241 M | 257 M | 286 M | 329 M | 362 M | 276 M | 297 M | 335 M | 368 M | 340 M | 295 M | 278 M | 237 M | 261 M | 264 M | 259 M | 188 M | 157 M | 185 M | 210 M | 157 M |
Cash and Cash Equivalents |
- | - | - | - | 225 M | 387 M | 514 M | 433 M | 220 M | 460 M | 550 M | 190 M | 243 M | 171 M | 200 M | 727 M | 161 M | 509 M | 501 M | 516 M | 159 M | 279 M | 131 M | 79.5 M | 90.7 M | 102 M | 122 M | 140 M | 156 M | 181 M | 217 M | 241 M | 163 M | 188 M | 201 M | 203 M | 222 M | 181 M | 179 M | 136 M | 156 M | 166 M | 144 M | 88.2 M | 57.6 M | 77.9 M | 97.6 M | 57.6 M |
Book Value |
- | - | - | - | 785 M | 901 M | 1.08 B | 1.18 B | 1.19 B | 1.28 B | 1.34 B | 1.09 B | 1.17 B | 1.24 B | 1.28 B | 1.33 B | 687 M | 610 M | 638 M | 685 M | 339 M | 348 M | 189 M | 140 M | 169 M | 210 M | 218 M | 241 M | 257 M | 286 M | 329 M | 362 M | 276 M | 297 M | 335 M | 368 M | 340 M | 295 M | 278 M | 237 M | 261 M | 264 M | 259 M | 188 M | 157 M | 185 M | 210 M | 157 M |
Total Shareholders Equity |
- | - | - | - | 673 M | 801 M | 971 M | 1.09 B | 1.08 B | 1.17 B | 1.24 B | 988 M | 1.07 B | 1.15 B | 1.2 B | 1.24 B | 606 M | 531 M | 559 M | 584 M | 207 M | 219 M | 82.8 M | 26.6 M | 39.9 M | 3.33 M | 13.6 M | 37.6 M | 53.5 M | 82.2 M | 107 M | 129 M | 47.3 M | 76.3 M | 103 M | 126 M | 91.9 M | 112 M | 125 M | 80.4 M | 98.6 M | 117 M | 108 M | 44.8 M | 10.6 M | 35.1 M | 60.2 M | 10.6 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Arena Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
